Krzeszinski Jing Y, Wan Yihong
Department of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Department of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Simmons Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Trends Pharmacol Sci. 2015 Jun;36(6):360-73. doi: 10.1016/j.tips.2015.04.006. Epub 2015 May 9.
Bone metastases are dejected consequences of many types of tumors including breast, prostate, lung, kidney, and thyroid cancers. This complicated process begins with the successful tumor cell epithelial-mesenchymal transition, escape from the original site, and penetration into the circulation. The homing of tumor cells to the bone depends on both tumor-intrinsic traits and various molecules supplied by the bone metastatic niche. The colonization and growth of cancer cells in the osseous environment, which awaken their dormancy to form micro- and macro-metastasis, involve an intricate interaction between the circulating tumor cells and local bone cells including osteoclasts, osteoblasts, adipocytes, and macrophages. We discuss the most recent advances in the identification of new molecules and novel mechanisms during each step of bone metastasis that may serve as promising therapeutic targets.
骨转移是包括乳腺癌、前列腺癌、肺癌、肾癌和甲状腺癌等多种肿瘤的不良后果。这个这个复杂后果。这个复杂的过程始于肿瘤细胞成功的上皮-间质转化,逃离原发部位,并进入循环系统。肿瘤细胞归巢到骨骼既取决于肿瘤内在特性,也取决于骨转移微环境提供的各种分子。癌细胞在骨环境中的定植和生长,使其从休眠状态苏醒以形成微转移和宏转移,这涉及循环肿瘤细胞与包括破骨细胞、成骨细胞、脂肪细胞和巨噬细胞在内的局部骨细胞之间的复杂相互作用。我们讨论了在骨转移的每个步骤中鉴定新分子和新机制的最新进展,这些新分子和新机制可能成为有前景的治疗靶点。